Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA
Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2026
DOI: 10.1177/23259582261420655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International Association of Providers of AIDS Care (JIAPAC), 2026. Verfasst von Marina Plesons und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: HIV Infections, Needle-Exchange Programs, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, ViiV Healthcare.
Abstract (Originalsprache)
Introduction
Long-acting injectable cabotegravir (CAB-LA) for preexposure prophylaxis (PrEP) is a promising HIV prevention tool for people who inject drugs (PWID), who face elevated HIV risk and barriers to care. While acceptable to PWID, CAB-LA implementation in low-barrier syringe services programs (SSPs) has not been examined.
Methods
From August 2023 to July 2025, we conducted semistructured interviews with 12 SSP staff involved in CAB-LA delivery. Interviews were transcribed and analyzed using thematic analysis guided by the Consolidated Framework for Implementation Research.
Results
Facilitators included CAB-LA's relative advantage over oral PrEP, external technical support, 340B pharmacy revenue, alignment with SSP mission and workflows, motivated staff, and financial incentives. Barriers included lack of FDA approval for PWID, complex logistics, performance pressures, infrastructure constraints, competing priorities, staff workload, and client outreach and engagement.
Conclusion
Integrating CAB-LA into SSPs is promising, but successful implementation requires targeted strategies, including additional resources, workflow adaptations, and enhanced outreach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
- Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Department of Population Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Health Behavior and Health Equity, University of Michigan School of Public Health, Ann Arbor, MI, USA.
ORCID-Profile: Marina Plesons, Elana Forman
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
- ViiV Healthcare
Zitieren
APA
Plesons, M., Forman, E., McDowell, E. C., Krakower, D., Amico, K. R., Groves, A. K., Roth, A., & Bartholomew, T. S. (2026). Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA. Journal of the International Association of Providers of AIDS Care (JIAPAC). https://doi.org/10.1177/23259582261420655
Vancouver
Plesons M, Forman E, McDowell EC, Krakower D, Amico KR, Groves AK, et al. Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2026. doi:10.1177/23259582261420655
BibTeX
@article{Plesons2026,
author = {Plesons, Marina and Forman, Elana and McDowell, Erin C and Krakower, Douglas and Amico, K Rivet and Groves, Allison K and Roth, Alexis and Bartholomew, Tyler S},
title = {Staff Perspectives on Implementation of Long-Acting Injectable Preexposure Prophylaxis at a Low-Barrier Syringe Services Program in Philadelphia, PA},
journal = {Journal of the International Association of Providers of AIDS Care (JIAPAC)},
year = {2026},
doi = {10.1177/23259582261420655}
}
EUVIMED